Evidence map›Paper›PMID 41403951›Full record

ArticleFrontiers in immunology2025

Prognostic and therapeutic implications of disulfidptosis-related genes in multiple myeloma.

Yunke Zang, Peipei Zhou, Haotian Dong, Jingfei Wang, Rongxuan Cao, Guimao Yang, Qianqian Wu, Yanhua Sun, Yanli Sun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yunke Zang *School of Medical Laboratory, Shandong Second Medical University, Weifang, China.
Peipei Zhou *School of Medical Laboratory, Shandong Second Medical University, Weifang, China.
Haotian DongSchool of Medical Laboratory, Shandong Second Medical University, Weifang, China.
Jingfei WangSchool of Medical Laboratory, Shandong Second Medical University, Weifang, China.
Rongxuan CaoDepartment of Hematology, Weifang People's Hospital, Weifang, China.
Guimao YangDepartment of Laboratory Medicine, Affiliated Hospital of Shandong Second Medical University, Weifang, China.
Qianqian WuDepartment of Laboratory Medicine, Affiliated Hospital of Shandong Second Medical University, Weifang, China.
Yanhua SunDepartment of Hematology, Weifang People's Hospital, Weifang, China.
Yanli SunSchool of Medical Laboratory, Shandong Second Medical University, Weifang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Multiple myeloma (MM), a malignancy of plasma cells in the bone marrow, urgently requires novel prognostic biomarkers. However, the prognostic significance of disulfidptosis-related genes and their association with treatment response in MM remain unclear. Methods: Transcriptomic data from MM samples were obtained from the Gene Expression Omnibus (GEO) database. A disulfidptosis-related prognostic model was constructed using LASSO-Cox regression analysis. The performance of the model was evaluated, and its clinical relevance to treatment response was subsequently assessed. Finally, the expression of the identified genes was validated by qRT-PCR and Western blotting. Results: Unsupervised cluster analysis identified a total of 121 differentially expressed genes. LASSO-Cox regression subsequently revealed a nine-gene prognostic signature comprising TPST2, HIF1A, KIF21B, MCPH1, MAST4, ANXA2, ALG14, PQLC3, and RANGAP1, which were used to establish and validate a robust risk stratification model. Partial validation demonstrated that ALG14, MCPH1, and PQLC3 were significantly downregulated, whereas TPST2 was markedly upregulated in MM cells. Conclusion: We established and validated a novel disulfidptosis-related prognostic model for MM, providing a potential biomarker for risk stratification and guidance for personalized therapeutic decisions.

Indexed as

Biomarkers, TumorMultiple MyelomaDatabases, GeneticDisulfidptosisFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisTranscriptomeBiomarkers, Tumordisulfidptosisgenemultiple myelomaprognostic signaturerisk stratification model

Identifiers

PMID41403951
PMCPMC12702948

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.